Drugs online research references
eucmax.sim.ucm.es
Administration of a dose of 15 mg/kg of the recreationally used drug 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") to Dark Agouti rats resulted in an acute hyperthermic response which was followed 7 days later by a marked (approximately 45%) loss of 5-HT and its metabolite 5-HIAA in cortex, hippocampus and striatum and a similar loss of [3H]-paroxetine binding in cortex. These losses reflect the MDMA-induced neurotoxic degeneration of 5-HT nerve endings. Administration of pentobarbitone (40 mg/kg) concurrently with MDMA produced a significant attenuation of the neurotoxic damage, but also acute hypothermia. When the temperature of the MDMA plus pentobarbitone-treated group was kept elevated to that of the MDMA-treated group by the use of a homeothermic blanket, the neuroprotective effect of pentobarbitone was lost. These data demonstrate that pentobarbitone appears to possess no intrinsic neuroprotective activity and the previously reported activity is due to a hypothermic action of the drug.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10229068&dopt=Abstract
note: kwd match paxil online literature
www.unime.it
SUMMARY: The effects of paroxetine on steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) were studied in 10 patients with schizophrenia or schizoaffective disorder. Patients stabilized using risperidone therapy (4-8 mg/d) also received paroxetine (20 mg/d) for 4 weeks. During paroxetine administration, mean plasma concentrations of risperidone increased significantly (P < 0.01), whereas levels of 9-OH-risperidone decreased slightly but not significantly. After 4 weeks of paroxetine treatment, the sum of the concentrations of risperidone and 9-OH-risperidone (active moiety) increased significantly by 45% (P < 0.05) over baseline. The mean plasma risperidone/9-OH-risperidone ratio was also significantly modified (P < 0.001) during paroxetine treatment. The drug combination was generally well tolerated with the exception of one patient who developed Parkinsonian symptoms in the second week of adjunctive therapy. In this patient total plasma levels of risperidone and its active metabolite increased by 62% during paroxetine co-administration. The authors' findings indicate that paroxetine, a potent inhibitor of CYP2D6, may impair the elimination of risperidone, primarily by inhibiting CYP2D6-mediated 9-hydroxylation and to a lesser extent by simultaneously affecting the further metabolism of 9-OH-risperidone or other pathways of risperidone biotransformation. Careful clinical observation and possibly monitoring of plasma risperidone levels may be useful whenever paroxetine is co-administered with risperidone.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11360029&dopt=Abstract
note: kwd match paxil online literature
Nutr Hosp. 2001 Jan-Feb;16(1):19-22.
[Changes in intake pattern in obese patients treated with paroxetine]
[Article in Spanish]
de Luis DA, de Luis J, Aller R, Romero E.
Instituto de Endocrinologia y Nutricion (IEN), Facultad de Medicina y Hospital Rio Hortega, Universidad de Valladolid, Espana.
GOAL: Drugs used in cases of obesity can be classified in several groups: those which increase thermogenesis; those which reduce the absorption of fats; and those which reduce the appetite. It seems that the last named group affects the intake pattern. The goal of our study was to assess the change in eating habits and the adherence to the diet by obese patients treated with paroxetin. SCOPE: The population studied comprised 14 obese patients. All of them were prescribed a diet of 1,500 calories/day in two groups: Group I (n = 7; only diet) and Group II (n = 7; diet plus paroxetin). After three months, a 24-hour nutritional survey was carried out to compare habitual intake with recommended intake. RESULTS: The intake of Group I was significantly greater than in Group II in terms of total calories (2,094.2 +/- 415 calories/day) versus 1,403.4 +/- 368 cal/day; p < 0.05), grammes of protein (100.2 +/- 19.6 g/day versus 63.2 +/- 8.1 g/day; p < 0.05) and carbohydrates (218.8 +/- 60.8 g/day versus 164.3 +/- 64.1 g/day; p < 0.05), and there were no significant differences in the amount or type of fat eaten. There were differences in the consumption of iron (14.2 +/- 2.4 mg/day versus 8.7 +/- 1.7 mg/day; p < 0.05), phosphorus (1,623.5 +/- 301.9 mg/day versus 1,001.8 +/- 255.6 mg/day; p < 0.05) and potassium (3,820 +/- 1,629 mg/day versus 2,560 +/- 557 mg/day; p < 0.05), with the remainder of minerals and vitamins not presenting significant differences. In conclusion, paroxetin modifies the intake pattern by reducing the amounts of calorie, proteins and carbohydrates consumed.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11367857&dopt=Abstract
note: kwd match paxil online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||